Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence

Anna Elisa Quatrale, Daniela Petriella, Letizia Porcelli, Stefania Tommasi, Nicola Silvestris, Giuseppe Colucci, Angelo Paradiso, Amalia Azzariti

Research output: Contribution to journalArticle

Abstract

The complexity of EGFR signaling network suggests that the receptor could be promising targets for new personalised therapy. In clinical practice two strategies targeting the receptor are available; they utilise monoclonal antibodies, directed towards the extracellular domain of EGFR, and small molecule tyrosine kinase inhibitors, which bind the catalytic kinase domain of the receptor. In this review, we summarise currently known pre-clinical data on the antitumor effects of monoclonal antibodies, which bind to EGFR in its inactive configuration, competing for ligand binding and thereby blocking ligand-induced EGFR tyrosine kinase activation. As a consequence of treatment, key EGFR-dependent intracellular signals in cancer cells are affected. Data explaining the mechanisms of action of anti-EGFR monoclonal antibodies, currently used in clinical setting and under development for the treatment of solid tumors, are revised with the aim to provide an overview of the most important preclinical studies showing the impact of this class of EGFR targeted agents on tumor biology.

Original languageEnglish
Pages (from-to)1973-1985
Number of pages13
JournalFrontiers in Bioscience
Volume16
Issue number5
DOIs
Publication statusPublished - Jan 1 2011

Fingerprint

Oncology
Monoclonal Antibodies
Protein-Tyrosine Kinases
Tumors
Ligands
Neoplasms
Catalytic Domain
Phosphotransferases
Chemical activation
Cells
Molecules
In Vitro Techniques
Therapeutics

Keywords

  • Cetuximab
  • IMC-11F8
  • Matuzumab
  • Nimotuzumab
  • Panitumimab
  • Review
  • Zalutumumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Anti-EGFR monoclonal antibody in cancer treatment : In vitro and in vivo evidence. / Quatrale, Anna Elisa; Petriella, Daniela; Porcelli, Letizia; Tommasi, Stefania; Silvestris, Nicola; Colucci, Giuseppe; Paradiso, Angelo; Azzariti, Amalia.

In: Frontiers in Bioscience, Vol. 16, No. 5, 01.01.2011, p. 1973-1985.

Research output: Contribution to journalArticle

Quatrale, Anna Elisa ; Petriella, Daniela ; Porcelli, Letizia ; Tommasi, Stefania ; Silvestris, Nicola ; Colucci, Giuseppe ; Paradiso, Angelo ; Azzariti, Amalia. / Anti-EGFR monoclonal antibody in cancer treatment : In vitro and in vivo evidence. In: Frontiers in Bioscience. 2011 ; Vol. 16, No. 5. pp. 1973-1985.
@article{13997e0aab874e399d94121c81d4fada,
title = "Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence",
abstract = "The complexity of EGFR signaling network suggests that the receptor could be promising targets for new personalised therapy. In clinical practice two strategies targeting the receptor are available; they utilise monoclonal antibodies, directed towards the extracellular domain of EGFR, and small molecule tyrosine kinase inhibitors, which bind the catalytic kinase domain of the receptor. In this review, we summarise currently known pre-clinical data on the antitumor effects of monoclonal antibodies, which bind to EGFR in its inactive configuration, competing for ligand binding and thereby blocking ligand-induced EGFR tyrosine kinase activation. As a consequence of treatment, key EGFR-dependent intracellular signals in cancer cells are affected. Data explaining the mechanisms of action of anti-EGFR monoclonal antibodies, currently used in clinical setting and under development for the treatment of solid tumors, are revised with the aim to provide an overview of the most important preclinical studies showing the impact of this class of EGFR targeted agents on tumor biology.",
keywords = "Cetuximab, IMC-11F8, Matuzumab, Nimotuzumab, Panitumimab, Review, Zalutumumab",
author = "Quatrale, {Anna Elisa} and Daniela Petriella and Letizia Porcelli and Stefania Tommasi and Nicola Silvestris and Giuseppe Colucci and Angelo Paradiso and Amalia Azzariti",
year = "2011",
month = "1",
day = "1",
doi = "10.2741/3834",
language = "English",
volume = "16",
pages = "1973--1985",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "5",

}

TY - JOUR

T1 - Anti-EGFR monoclonal antibody in cancer treatment

T2 - In vitro and in vivo evidence

AU - Quatrale, Anna Elisa

AU - Petriella, Daniela

AU - Porcelli, Letizia

AU - Tommasi, Stefania

AU - Silvestris, Nicola

AU - Colucci, Giuseppe

AU - Paradiso, Angelo

AU - Azzariti, Amalia

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The complexity of EGFR signaling network suggests that the receptor could be promising targets for new personalised therapy. In clinical practice two strategies targeting the receptor are available; they utilise monoclonal antibodies, directed towards the extracellular domain of EGFR, and small molecule tyrosine kinase inhibitors, which bind the catalytic kinase domain of the receptor. In this review, we summarise currently known pre-clinical data on the antitumor effects of monoclonal antibodies, which bind to EGFR in its inactive configuration, competing for ligand binding and thereby blocking ligand-induced EGFR tyrosine kinase activation. As a consequence of treatment, key EGFR-dependent intracellular signals in cancer cells are affected. Data explaining the mechanisms of action of anti-EGFR monoclonal antibodies, currently used in clinical setting and under development for the treatment of solid tumors, are revised with the aim to provide an overview of the most important preclinical studies showing the impact of this class of EGFR targeted agents on tumor biology.

AB - The complexity of EGFR signaling network suggests that the receptor could be promising targets for new personalised therapy. In clinical practice two strategies targeting the receptor are available; they utilise monoclonal antibodies, directed towards the extracellular domain of EGFR, and small molecule tyrosine kinase inhibitors, which bind the catalytic kinase domain of the receptor. In this review, we summarise currently known pre-clinical data on the antitumor effects of monoclonal antibodies, which bind to EGFR in its inactive configuration, competing for ligand binding and thereby blocking ligand-induced EGFR tyrosine kinase activation. As a consequence of treatment, key EGFR-dependent intracellular signals in cancer cells are affected. Data explaining the mechanisms of action of anti-EGFR monoclonal antibodies, currently used in clinical setting and under development for the treatment of solid tumors, are revised with the aim to provide an overview of the most important preclinical studies showing the impact of this class of EGFR targeted agents on tumor biology.

KW - Cetuximab

KW - IMC-11F8

KW - Matuzumab

KW - Nimotuzumab

KW - Panitumimab

KW - Review

KW - Zalutumumab

UR - http://www.scopus.com/inward/record.url?scp=79954993078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954993078&partnerID=8YFLogxK

U2 - 10.2741/3834

DO - 10.2741/3834

M3 - Article

C2 - 21196277

AN - SCOPUS:79954993078

VL - 16

SP - 1973

EP - 1985

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 5

ER -